Immutep has entered into a clinical trial collaboration agreement, a supply agreement and a service agreement with CYTLIMIC Inc. for its lead product candidate eftilagimod alpha as part of a cancer vaccine. The companies will collaborate on clinical trials to evaluate efti as part of a therapeutic cancer vaccine containing CYTLIMIC’s cancer peptide vaccine, called CYT001. CYTLIMIC will conduct the trials and fund all development costs. Immutep will receive $500,000 upfront and is eligible ...